---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-25-029350"
form_type: "8-K"
ticker: "IMCR"
cik: "0001671927"
company_name: "Immunocore Holdings plc"
filed_at: "2025-08-07T23:59:59+00:00"
generated_at: "2026-05-17T17:45:50.084487+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Immunocore Q2 2025: KIMMTRAK revenue $98M (+30% YoY); net loss $10.3M

## Summary
- Q2 2025 net product sales of $98.0M, up 30% vs. $75.3M in Q2 2024; US sales $64.1M, Europe $33.0M.
- Net loss of $10.3M ($0.20 per share) compared to net loss of $11.6M ($0.23 per share) in Q2 2024.
- Cash, equivalents & marketable securities of $882.8M as of June 30, 2025; expects ~$65M in rebate payouts.
- Phase 3 TEBE-AM trial (cutaneous melanoma) on track to complete enrollment in 1H 2026.
- PRISM-MEL-301 (brenetafusp) dose selection expected in 2H 2025; IDMC recommended continue with no changes.

## SEC filing metadata
- accession: 0001140361-25-029350
- form_type: 8-K
- ticker: IMCR
- cik: 0001671927
- company_name: Immunocore Holdings plc
- filed_at: 2025-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1671927/000114036125029350/0001140361-25-029350-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1671927/000114036125029350/ef20053240_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-25-029350
- JSON: https://secwatch.observer/filing/0001140361-25-029350.json
- Plain text: https://secwatch.observer/filing/0001140361-25-029350.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.